RESULTS

RESULTS

* Tables (1), (2), (3) and (4) show the clinical and laboratory data in the different groups in the present work.

* Table (5) shows the plasma antithrombin III level among the studied groups. There is a significant decrease in AT III level in uremic patients with regular hemodialysis before session as compared to the control group. There is no significant decrease in AT III level in uremic patients with regular hemodialysis after session as compared to the control group. There is a significant decrease in AT III level in uremic patients with conservative treatment as compared to the control group.

* Table (6) shows partial thromboplastin time among the studied groups. There is a significant increase in partial thromboplastin time in uremic patients with regular hemodialysis before and after session as compared to the control group. There is a significant increase in partial thromboplastin time in uremic patient with conservative treatment as compared to the control group.

* Table (7) shows platelet count among the studied groups. There is a significant decrease in platelet count in uremic patients with regular hemodialysis before and after session as

compared to the control group. There is no significant decrease in platelet count in uremic patients with conservative treatment as compared to the control group.

* Table (8) shows value of antithrombin III, partial thromboplastin time and platelet count before and after session among uremics under regular dialysis. There is a significant increase in AT III level after session. There is no significant decrease in partial thromboplastin time after session. There is no significant decrease in platelet count after session.

* Table (9) represents the correlation coefficient and probability value between AT III versus partial thromboplastin time and platelet count among studied groups. There is no significant negative correlation between AT III and partial thromboplastin time among the studied groups. There is no significant positive correlation between AT III and platelet count among the studied groups.

* Table (10) represents the correlation coefficient and probability value between AT III versus partial thromboplastin time and platelet count among uremic patients with regular hemodialysis before session. There is no significant negative correlation between AT III and partial thromboplastin time among the uremic patients with regular hemodialysis before session. There is no significant positive correlation between AT III and platelet count among uremic patients with regular hemodialysis before session.

* Table (11) represents the correlation coefficient and probability value between AT III versus partial thromboplastin time and platelet count among uremic patients with regular hemodialysis after session. There is no significant positive correlation between AT III and partial thrombo plastin time among uremic patients with regular hemodialysis after sessiion. There is no significant correlation between AT III and platelet count among uremic patients with regular hemodialysis after session.

* Table (12) represents the correlation coefficient and probability value between AT III versus partial thromboplastin time and platelet count among uremic patients with conservative treatment. There is no significant negative correlation between AT III and partial thromboplastin time among uremic patients with conservative treatment. There is no signicicant positive correlation between AT III and platelet count among uremic patients with conservative treatment.

* Table (13) shows serum creatinine among the studied groups. There is a significant increase in serum creatinine in uremic patients with regular hemodialysis before session as compared with control group. There is a significant increase in serum creatinine in uremic patients with regular hemodialysis after session as compared with control group there is a significant increase in serum creatinine in uremic patients with conservative treatment as compared with control group.

* Table (14) shows blood urea among the studied groups. There is a significant increase in blood urea in uremic patients with regular hemodialysis before session as compared with control group. There is a significant increase in blood urea in uremic patients with regular hemodialysis after session as compared with control group. There is a significant increase in blood urea in uremic patients with conservative treatment as compared with control group.

* Table (15) shows sex distribution of the studied groups.

* Table (16) shows age distribuation of the studied groups.

Table (1): Clinical and Laboratory data of control group

	Sex	Age (y)	AT III (mg/dl)	PTT (sec.)	Plat. count (1000/cmm)	Urea (mg/dl)	Creatinine (mg/dl)
1	M	25	244	30	250	22	0.7
2	M	36	375	34	280	16	0.9
3	F	40	360	39	260	21	0.8
4	M	42	330	38	210	23	1.1
5	M	37	272	33	300	19	0.8
6	F	50	246	29	290	24	0.6
7	M	28	300	35	270	30	0.7
8	M	40	315	41	210	23	0.8
9	M	38	300	32	230	22	0.9
10	F	33	329	37	280	17.5	0.6
Mean		36.9	307.1	34.8	258.0	21.7	0.79
S.D+		7.1	44.1	3.9	32.2	3.8	0.15

M: Male
F: Female
PTT: Partial thromboplastin time
S.D.: Standard deviation

Y: Yeal
AT III: Antithrombin I
Plat. count: Platelet count

Table (2): Clinical and Laboratory data of uraemic patients with conservative treatment.

	Sex	Age (y)	AT III (mg/dl)	PTT (sec.)	Plat. count (1000/cmm)	Urea (mg/dl)	Creatinine (mg/dl)
1	M	43	258	38	282	130	3.9
2	M	28	250	40	274	150	4.6
3	M	36	192	39	260	180	7.5
4	M	40	158	42	280	193	8
5	F	43	315	40	230	210	9.1
6	M	52	180	45	255	110	5.8
7	F	38	156	36	218	130	6
8	M	27	218	45	280	178	7.6
9	M	48	143	43	216	212	10
10	M	50	156	44	250	120	6
Mean		40.5	202.6	41.2	254.5	160.5	6.8
S.D.+		8.5	56.4	3.08	25.6	37.6	1.9

M: Male
F: Female
PTT: Partial thromboplastin time
S.D.: Standard deviation

Y: Year
AT III: Antithrombin III
Plat. count: Platelet count

79

Table (3): Clinical and laboratory data of uremic patients undergoing regular hemodialysis (before session).

	Sex	Age (y)	AT III mg/dl	PTT Sec.	Plat count (1000/cmm)	Urea mg/dl	Creatinine mg/dl
1	M	22	218	35	250	140	13
2	M	32	228	56	190	141	12.5
3	M	44	244	31	250	277	14
4	M	39	258	45	220	250	10.5
5	F	55	250	49	180	240	15.2
6	M	53	198	30	210	185	10
7	M	49	220	45	160	225	16
8	M	38	199	52	190	160	14
9	F	45	286	45	200	212	12
10	M	37	180	40	210	200	11.2
11	M	35	205	56	230	180	11
12	F	28	218	31	250	228	16
13	F	42	231	44	310	190	12
14	M	53	244	49	180	230	15
15	M	55	286	30	230	260	14.6
16	M	27	192	42	280	220	10
17	M	49	210	47	240	270	14
18	F	33	315	38	190	198	13
19	M	38	329	51	250	150	11
20	M	42	286	47	220	230	15
Mean		40.8	227.1	43.1	222.0	209.3	13.0
S.D.+		9.6	64.8	8.3	36.9	41.3	1.9

M   : Male   y : year
F   : Female
AT III   : Antithrombin III
PTT   : Partial thromboplastin time
Plat. count: Platelet count
S.D.   : Standard deviation

80

Table (4): Clinical and laboratory data of uremic patients
undergoing regular hemodialysis (after session).

	Sex	Age (y)	AT III mg/dl	PTT Sec.	Plat. count (1000/cmm)	Urea mg/dl	Creatinine mg/dl
1	M	22	360	44	230	100	9
2	M	32	286	45	180	105	6
3	M	44	286	40	220	160	11
4	M	39	258	42	210	185	10
5	F	55	305	46	230	130	6
6	M	53	244	30	180	120	5.5
7	M	49	286	53	210	95	5
8	M	38	210	35	189	160	10
9	F	37	250	35	200	120	7
10	M	35	329	40	230	100	8
11	M	28	277	39	250	150	9
12	F	42	286	42	230	140	7.8
13	F	53	310	40	185	120	5.5
14	M	45	286	39	220	130	6.2
15	M	55	344	44	300	105	5.8
16	M	27	210	42	160	160	9
17	M	49	272	38	290	120	8
18	F	33	329	31	212	170	7.9
19	M	38	360	42	230	100	8.3
20	M	42	286	44	210	100	9
Mean		40.8	288.6	40.5	218.3	128.5	7.6
S.D.+		9.6	42.6	5.2	34.3	27.3	1.7

M   : Male   y : year
F   : Female
AT III   : Antithrombin III
PTT   : Partial thromboplastin time
Plat. count : Platelet count
S.D.   : Standard deviation

81

Table (5): Plasma antithrombin III level among the studied groups.

	X'	S.D.	Test of significance versus controls	
			T	P
* U. + R.D.				
(a) Before session	227.1	64.8	3.50	<0.05
(b) After session	288.6	42.6	1.12	>0.05
* U. + C.T.	202.6	56.4	4.61	<0.05
* Controls	307.1	44.1		

U. + R.D. = Uraemics under regular dialysis.
U. + C.T. = Uraemics under conservative treatment.
X'= Mean.   S.D.= Standard Deviation.

Table (6): PTT among the Studied groups.

	X'	S.D.	Test of significance versus controls	
			T	P
* U.+ R.D.				
(a) Before session	43.1	8.3	2.98	<0.05
(b) After session	40.5	5.2	3.04	<0.05
* U.+ C.T.	41.2	3.1	4.04	<0.05
* Controls	34.8	3.9		

U.+ R.D. = Uraemics under regular dialysis.
U.+ C.T. = Uraemics under conservative treatment.
X'= Mean.   S.D.= Standard Deviation.

Table (7): Platelet count among the studied groups.

	X'	S.D.	Test of significance versus controls	
			T	P
* U.+ R.D.				
(a) Before session	222	36.9	2.62	<0.05
(b) After session	218	34.3	3.04	<0.05
* U.+ C.T.	254	25.6	0.27	>0.05
* Controls	258	32.2		

U.+ R.D. = Uraemics under regular dialysis.
U.+ C.T. = Uraemics under conservative treatment.
X'= Mean.
S.D.= Standard Deviation.

Table (8): Value of AT III, PTT and Pl. count before and after session among uraemics under regular dialysis (U.+R.D.)

	Before		After		Paired t test	P
	X'	S.D.	X'	S.D.		
AT III	227.1	64.8	288.6	42.6	4.07	<0.05
PTT	43.1	8.3	40.5	5.2	1.28	>0.05
Pl.count.	222	36.9	218	34.3	0.32	>0.05

AT III   =   Antithrombin III
PTT   =   Partial thromboplastin time
Pl.count =   Platelet coun
X'   =   Mean   S.D.   =   Standar Deviation

Table (9): Correlation coefficient (r) and probability value (p)
between At III versus PTT and Pl. count amoung studied
groups:

	AT III	
	r	p
PTT	-0.0519	>0.05
Pl. count	0.0446	>0.05

Table (10): Correlation coefficient (r) and Probability value (p)
between At III versus PTT and Pl. count amoung
U.+R.D. (befor session).

	AT III	
	r	p
PTT	-0.1097	>0.05
Pl. count	0.112	>0.05

- AT III   = Antithrombin III   - Pl. count = Platelet count.

- PTT   = Partial thromboplastin time.

- U.+ R.D. = Uraemics under regular dialysis.

Table (11): Correlation coefficient (r) and probabitity value (p) between At III versus PTT and Pl. count among U.+R.D. (after session).

	AT III	
	r	p
PTT	0.276	>0.05
Pl. count	0.504	>0.05

- U.+ R.D. = Uraemics under regular dialysis.

Table (12): Correlation coefficient (r) and probability value (p) between At III versus PTT and Pl.count among U.+ C.T.

	AT III	
	r	p
PTT	-0.2579	>0.05
Pl. count	0.2370	>0.05

- AT III   = Antithrombin III.   - Pl. count = Platelet count.

- PTT   = Partial thromboplastin time.

- U.+ C.T.   = Uraemics under conservative treatment.

Table (13): Serum creatinine among the studied groups.

	X'	S.D.	Test of significance versus controls	
			T	P
* U.+ R.D.				
(a) Before session	13.0	1.9	19.34	<0.01
(b) After session	7.6	1.7	12.35	<0.05
* U.+ C.T.	6.8	1.9	9.88	<0.01
* Controls	0.8	0.2		

U.+ R.D. = Uraemics under regular dialysis.
U.+ C.T. = Uraemics under conservative treatment.
X'   = Mean.
          S.D.= Standard Deviation.

Table (14): Blood urea among the studied groups.

	X'	S.D.	Test of significance versus controls	
			T	P
* U.+ R.D.				
(a) Before session	209.3	41.3	14.19	<0.01
(b) After session	128.5	27.3	12.15	<0.01
* U.+ C.T.	160.5	37.6	11.57	<0.01
* Controls	21.7	3.8		

U.+ R.D. = Uraemics under regular dialysis.
U.+ C.T. = Uraemics under conservative treatment.
X'   = Mean.
S.D.= Standard Deviation.

Table (15): Sex distribuation of studied groups.

		Males		Females		Total	
		No	%	No	%	No	%
* U.+ R.D.		15	75.0	5	25.0	20	100.0
* U.+ C.T.		8	80.0	2	20.0	10	100.0
Control		7	70.0	3	30.0	10	100.0
Total		30	75.0	10	25.0	40	100.0

U.+ R.D. = Uraemics under regular dialysis.
U.+ C.T. = Uraemics under conservative treatment.
X' = Mean.
S.D.= Standard Deviation.

Table (16): Age distribuation of studied groups.

	<45		45+		Total	
	No	%	No	%	No	%
* U.+ R.D.	10	50.0	10	50.0	20	100.0
* U.+ C.T.	4	40.0	6	60.0	10	100.0
Control	6	60.0	4	40.0	10	100.0
Total	20	50.0	20	50.0	40	100.0

U.+ R.D. = Uraemics under regular dialysis.
U.+ C.T. = Uraemics under conservative treatment.
X'   =   Mean.
S.D.= Standard Deviation.

Fig.(1): Plasma antithrombin III level among the studied groups.

UD (b.S.): Uremics with regular dialysis before session.

UD (a.S.): Uremics with regular dialysis after session.

UCT : Uremics with conservative treatment.

Fig.(2): P.T.T. among the studied groups.

PTT : Partial thromboplastin time.

UD (b.S.): Uremics with regular dialysis before session.

UD (a.S.): Uremics with regular dialysis after session.

UCT : Uremics with conservative treatment.

Fig. *(3):* *AT III,P.T.T.and Pl.count before and after session among uraemics under regular dialysis.*


PTT: Partial thromboplastin time.

AT III: Anti thrombin III.

Pl. count: Platelet count.

Fig.(4): Relationship between AT III and Pl.
count among uraemics under dialysis
after session.

- AT III = Antithrombin III.
- Pl. count = Platelet count.

Fig.(5): Relationship between AT III and P.T.T.

among uraemics under conservative

treatment.

PTT: Partial thromboplastin time.

AT III: Anti thrombin III.